Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: A clinicopathologic study of 160 liver biopsy specimens

Archives of Dermatology

Volumn 143, Issue 12, 2007, Pages 1515-1519

  Berends, Maartje A M ^a   Van Oijen, Martijn G H ^a   Snoek, Josje ^a   Van De Kerkhof, Peter C M ^a   Drenth, Joost P H ^a   Van Krieken, J Han ^a   De Jong, Elke M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPPA STATISTICS; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; RELIABILITY; RETROSPECTIVE STUDY; ROENIGK CLASSIFICATION; SCORING SYSTEM;

BIOPSY; DERMATOLOGIC AGENTS; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; METHOTREXATE; PSORIASIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 34447540604     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.12.1515     Document Type: Article

References (25)

1. Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther. 2004;19(4):391-399.
2. Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol. 1995;133(5):774-778.
3. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy, 3: findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A. 1977;85(4):511-518.
4. Roenigk HH Jr, Maibach HI, Weinstein GP. Methotrexate therapy for psoriasis: guideline revisions. Arch Dermatol. 1973;108(1):35.
5. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol. 2000;42(3):531-544.
6. Zachariae H, Grunnet E, Sogaard H. Liver biopsy in methotrexate-treated psoriatics: a re-evaluation. Acta Derm Venereol. 1975;55(4):291-296.
7. Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther. 2004;20(3):249-259.
8. Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J Clin Rheumatol. 2001;7(4):224-227.
9. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38(3):478-485.
10. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495-500.
11. Chalmers RJ, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol. 2005;152(3):444-450.
12. MacDonald A, Burden AD. Noninvasive monitoring for methotrexate hepatotoxicity. Br J Dermatol. 2005;152(3):405-408.
13. Maurice PD, Maddox AJ, Green CA, Tatnall F, Schofield JK, Stott DJ. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol. 2005; 152(3):451-458.
14. Roenigk HH, Auerbach R, Weinstein GD. Use of methotrexate in psoriasis. Arch Dermatol. 1972;105(3):363-365.
15. Richard S, Guerret S, Gerard F, Tebib JG, Vignon E. Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semiquantitative scoring system. Rheumatology (Oxford). 2000;39(1):50-54.
16. West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am. 1997;23(4):883-915.
17. Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol. 2001;144(1):100-103.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
19. Cicchetti DV, Feinstein AR. High agreement but low κ, II: resolving the paradoxes. J Clin Epidemiol. 1990;43(6):551-558.
20. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1, pt 1):15-20.
21. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31(1):241-246.
22. Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol. 1996;25(5):649-654.
23. Hunt N, Fleming K. Reproducibility of liver biopsy grading and staging. Liver. 1999;19(3):169-170.
24. Westin J, Lagging LM, Wejstål R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver. 1999;19(3):183-187.
25. Berends MA, Snoek J, de Jong EM, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts presence and Fibroscan® predicts the absence of significant liver fibrosis. Liver Int. 2007;27(5):639-645.